TelyRx to go public via a SPAC merger with Apolo V Acquisition Corp in a $46m deal.

TelyRx, a technology-enabled healthcare company, agreed to go public via a SPAC merger with Apolo V Acquisition Corp, a capital pool company, in a $46m deal. "As we take TelyRx public, we're advancing a simple but powerful mission: to make access to everyday prescription medication safer, faster, and more transparent. TelyRx was founded by healthcare industry veterans, which is why, from day one, we've prioritized compliance, clinical integrity, and patient trust. Our risk-curated formulary of FDA-approved medications, our nationwide network of independent licensed providers, and our intuitive, patient-first platform all work in concert to deliver a seamless care experience," Vanessa Slowey, TelyRx CEO.